New: Evolving the Heatmap: Dow Jones, Nasdaq 100, Russell 2000, and More

Amneal Pharmaceuticals LLC

Contributing Author

Recent Articles by Amneal Pharmaceuticals LLC

Sep-30	Amneal to Report Third Quarter 2025 Results on October 30, 2025 AMRX GlobeNewswire
Sep-26	Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR (omalizumab) AMRX GlobeNewswire
Sep-23	Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01% AMRX GlobeNewswire
Sep-11	Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution AMRX GlobeNewswire
Sep-04	Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension AMRX GlobeNewswire
Aug-05	Amneal Reports Second Quarter 2025 Financial Results AMRX GlobeNewswire
Jul-21	Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032 AMRX GlobeNewswire
Jul-21	Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results AMRX GlobeNewswire
Jul-09	Amneal to Report Second Quarter 2025 Results on August 5, 2025 AMRX GlobeNewswire
Jun-25	Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences AMRX GlobeNewswire
Jun-12	Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension AMRX GlobeNewswire
May-29	Amneal to Participate at Upcoming Investor Conferences in June AMRX GlobeNewswire
May-15	Amneal Receives U.S. FDA Approval for Brekiya (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults AMRX GlobeNewswire
May-08	Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S. AMRX GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.